Notably, giredestrant exhibited positive outcomes in reducing Ki67 expression and inducing complete cell cycle arrest when used as neoadjuvant therapy in previously untreated patients with hormone receptor-positive, HER2-negative early breast cancer in the coopERA study (8, 44). Here, NR4A1 is linked to breast carcinoma.